Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIb clinical study of PDS-0101 in combination with other immune-modulating agents in HPV16-positive and HIV-positive subjects with high-grade anal intraepithelial neoplasia (anal pre-cancer)

Next Previous
Trial Profile

A phase IIb clinical study of PDS-0101 in combination with other immune-modulating agents in HPV16-positive and HIV-positive subjects with high-grade anal intraepithelial neoplasia (anal pre-cancer)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PDS 0101 (Primary)
  • Indications Anal intraepithelial neoplasia
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Mar 2022 According to an PDS Biotechnology Corporation, updates from this study will be presented at the Oppenheimer's 32nd Annual Virtual Healthcare Conference, 2022.
    • 18 Jan 2022 According to a PDS Biotechnology Corporation media release, data from this trial will be presented at the B. Riley Securities Virtual Oncology Conference, 2022.
    • 29 Apr 2020 According to a PDS Biotechnology Corporation media release, Dr. Julius Strauss, Staff Clinician, will serve as the principal investigator of the phase 2 clinical trial of PDS0101 in advanced HPV-associated cancers
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top